---
schema_version: "secwatch.filing_event.v1"
accession: "0001367644-25-000121"
form_type: "8-K"
ticker: "EBS"
cik: "0001367644"
company_name: "Emergent BioSolutions Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T07:22:28.088240+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Emergent BioSolutions Q1 net income surges 656% to $68M; revenue down 26% to $222.2M

## Summary
- Total revenues $222.2M, down 26% YoY; driven by 62% drop in NARCAN sales to $45.3M.
- Net income $68.0M ($1.19 diluted EPS) vs $9.0M prior year; adjusted EBITDA $77.6M, up 16%.
- MCM Products segment revenues $156.6M (+1%), driven by 112% increase in Smallpox MCM to $106.4M.
- Board authorized $50M share repurchase through March 2026; reaffirmed FY 2025 revenue guidance $750-$850M.
- Recent deals: $20M BioThrax contract option, $16.7M BARDA collaboration, exclusive U.S./Canada rights to KLOXXADO.

## SEC filing metadata
- accession: 0001367644-25-000121
- form_type: 8-K
- ticker: EBS
- cik: 0001367644
- company_name: Emergent BioSolutions Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/0001367644-25-000121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1367644/000136764425000121/ebs-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001367644-25-000121
- JSON: https://secwatch.observer/filing/0001367644-25-000121.json
- Plain text: https://secwatch.observer/filing/0001367644-25-000121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.